Star Combo Pharma (ASX:S66) Risk Assessment

View and export this data going back to 2018. Start your Free Trial

What is Star Combo Pharma Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Star Combo Pharma is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Star Combo Pharma's Risk Assessment

For the Household & Personal Products subindustry, Star Combo Pharma's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Star Combo Pharma's Risk Assessment Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Star Combo Pharma's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Star Combo Pharma's Risk Assessment falls into.

Save Embed

;

Save Embed

;

Star Combo Pharma (ASX:S66) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Star Combo Pharma Risk Assessment Related Terms

Thank you for viewing the detailed overview of Star Combo Pharma's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Star Combo Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Star Combo Pharma Ltd (ASX:S66) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

171 - 177 Woodpark Road, Smithfield, Sydney, NSW, AUS, 2164

Website

https://www.starcombo.com.au

Star Combo Pharma Ltd is engaged in the manufacturing and distribution of food products and nutritional supplements. The company offers products such as face masks, moisturizing creams, serums, concentrates, and oils. Star Combo Pharma markets its products. It operates in two segments. Star Combo segment engages in the development, manufacturing, marketing and sales of natural health supplements and skincare products. The Austoyou retail business segment has made up of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers; and Koala Mall's two retail stores in Sydney. Geographically, it operates in China and Australia.

Star Combo Pharma Headlines

No Headlines